Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds.

doi:10.1248/CPB.31.798

Paper

Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds.

Published Mar 25, 1983 · Takao Nishi, Katsuyoshi Yamamoto, Takefumi Shimizu

Chemical & pharmaceutical bulletin

Q3 SJR score

25

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Many alkyl 4-(2-oxo-1, 2, 3, 4-tetrahydro-6-quinolyloxy) butyrates and related compounds were synthesized and tested for inhibitory activity against blood platelet aggregation in vitro. Among them, ethyl 4-(2-oxo-1, 2, 3, 4-tetrahydro-6-quinolyloxy) butyrate was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.

In Vitro Study

Study Snapshot

Ethyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy) butyrate shows the most potent inhibitory activity against blood platelet aggregation, suggesting potential applications in anticoagulant therapy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds.

Sign up to use Study Snapshot

References

Citations

Total Synthesis of Waltherione F, a Nonrutaceous 3-Methoxy-4-quinolone, Isolated from Waltheria indica L. F.

Waltherione F, a nonrutaceous 3-Methoxy-4-quinolone, was successfully synthesized in seven steps with 31% overall yield from 2-nitro-3-methylanisole without the use of protecting groups.

An organocatalytic asymmetric Mannich reaction for the synthesis of 3,3-disubstituted-3,4-dihydro-2-quinolones.

The organocatalytic asymmetric Mannich reaction effectively synthesizes biologically important 3,3-disubstituted-3,4-dihydro-2-quinolones with high enantio- and diastereoselectivity.

Organocatalytic Asymmetric Synthesis of 3,3‐Disubstituted 3,4‐Dihydro‐2‐quinolones

This study developed an organocatalytic asymmetric reaction for the synthesis of biologically important 3,3-disubstituted-dihydro-2-quinolones using cinchona alkaloid-derived bifunctional amino-thiourea catalysts.

ZnBr2 catalyzed domino Knoevenagel-hetero-Diels–Alder reaction: An efficient route to polycyclic thiopyranoindol annulated [3,4-c]quinolone derivatives

ZnBr2 catalyzed domino Knoevenagel-hetero-Diels-Alder reaction efficiently synthesizes novel polycyclic thiopyranoindol annulated [3,4-c]quinolone derivatives with high yields and excellent regio-

Radical C-H functionalization to construct heterocyclic compounds.

Radical C-H functionalization offers a promising and efficient approach for synthesizing heterocyclic compounds with high atom- and step-economy, benefiting organic and pharmaceutical chemists.

A novel direct synthesis of 3-acyl-4-aryldihydroquinolin-2(1H)-ones via metal-free radical tandem cyclization between N-arylcinnamamides and aldehydes

This study developed a metal-free, practical method for synthesis of 3-acyl-4-aryldihydroquinolin-2(1H)-ones in one step by C-H functionalization.

Metal-free synthesis of oxindoles via (NH4)2S2O8-mediated halocarbocyclization of alkenes in water.

This study demonstrates a metal-free, environmentally benign method for synthesis of halo-containing oxindoles in water, with good functional group tolerance and mild reaction conditions.

The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.

Clinical data for cilostazol and naftidrofuryl for intermittent claudication lack standardization, objective endpoints, and strict eligibility criteria, making it difficult to identify a true treatment effect.